



VEXT SCIENCE, INC.

**MANAGEMENT’S DISCUSSION AND ANALYSIS FOR THE NINE MONTHS ENDED
SEPTEMBER 30, 2021**

DATED AS OF NOVEMBER 17, 2021

(All amounts expressed in U.S. dollars, unless otherwise stated)

CAUTIONARY NOTE REGARDING FORWARDING LOOKING STATEMENTS

This Management’s Discussion and Analysis (“MD&A”) contains certain statements that may constitute “forward-looking statements”. Forward-looking statements include, but are not limited to, statements regarding future expansion, business goals, anticipated business developments and the timing thereof, regulatory compliance, sufficiency of working capital, business and financing plans, and other forward-looking statements including, but not limited to, information concerning intentions, plans and future actions of the Company.

In connection with the forward-looking information contained in this MD&A, the Company has made assumptions about the Company’s ability to expand operations; profitably license its brands, and operate in the future without any regulation or law imposed which would prevent the Company from operating its business. The Company has also assumed that no significant events occur outside of the Company's normal course of business.

The forward-looking information in this MD&A reflects the current expectations, assumptions and/or beliefs of the Company based on information currently available to the Company. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are typically identified by words such as: believe, expect, anticipate, intend, estimate, postulate and similar expressions, or which by their nature refer to future events. The Company cautions that any forward-looking statements by the Company are not guarantees of future performance, and that actual results may differ materially from those in forward looking statements as a result of various factors, including, but not limited to, the Company’s ability to continue its projected growth, to raise the necessary capital or to be fully able to implement its business strategies.

BACKGROUND

This MD&A has been prepared for the nine months ended September 30, 2021, and it presents an analysis of the consolidated financial position of Vext Science, Inc. (“Vext” or the “Company”) for the nine months ended September 30, 2021. The following information should be read in conjunction with the audited financial statements of the Company for the year ended December 31, 2020, including the notes contained therein. The consolidated financial statements are prepared in accordance with International Financial Reporting Standards (“IFRS”).

The consolidated financial statements of the Company include the financial statements of the Company and its direct subsidiaries, indirect subsidiaries that are not wholly owned by the Company and other entities consolidated other than on the basis of ownership:

Name	Jurisdiction	Ownership
Vext Science, Inc.	BC, Canada	100%
Subsidiaries:		
New Gen Holdings, Inc.	Wyoming, USA	100%
Step 1 Consulting, LLC	Delaware, USA	100%
New Gen Admin Services, LLC	Arizona, USA	100%
New Gen Agricultural Services, LLC	Arizona, USA	100%
New Gen Real Estate Services, LLC	Arizona, USA	100%
Hydroponics Solutions, LLC	Arizona, USA	100%
New Gen Phoenix (PHX), LLC	Arizona, USA	100%
New Gen Eloy, LLC	Arizona, USA	100%
New Gen Prescott (PV), LLC	Arizona, USA	100%
Pure Touch Botanicals, LLC	Arizona, USA	100%
Vapen, LLC	Arizona, USA	100%
Vapen CBD, LLC	Arizona, USA	100%
RDF Management, LLC	Arizona, USA	100%
Firebrand, LLC	Arizona, USA	100%
Joint Ventures:		
Vapen Kentucky, LLC	Kentucky, USA	50%
Vapen-Oklahoma, LLC	Oklahoma, USA	25%
Joint Operations:		
Happy Travels, LLC	California, USA	0%

Vext, through its wholly owned subsidiaries, currently operates in the U.S. as an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin cannabis THC and hemp CBD products under the Vapen and Pure Touch Botanicals brands. Vext's expansion plans include continuing to invest in expansion and efficiencies of AZ operations and partnering with cannabis license holders within the U.S.

New Gen Holdings, Inc. is a service company that provides services to Herbal Wellness Center Inc. ("HWC"), licensed dispensaries for medical marijuana products and extracts pursuant to licenses granted by the State of Arizona. On April 6, 2020, the Company acquired 100% membership interest in Firebrand, LLC and RDF Management, LLC, which owned management contracts to provide services to Organica Patient Group Inc., and Organica Patient Group Medical Marijuana Dispensary. As a result of this acquisition, the Company, through its operating subsidiaries, has management contracts with two licensed medical marijuana dispensaries in the State of Arizona.

During the period covered by this MD&A, the Company continued its expansion strategy by entering into additional joint venture agreements, management service agreements, and operating agreements with partners located in various states in the United States. As of the date of this MD&A, four of these relationships have commenced commercial operations.

MATERIAL EVENTS THAT OCCURRED DURING THREE MONTHS ENDED SEPTEMBER 30, 2021

On July 6, 2021, the Company announced that it has signed a Memorandum of Understanding (“MOU”) with SōRSE Technology Corp. (“SōRSE”) to exclusively produce and sell SōRSE’s MAJOR cannabis-infused beverages in Arizona. SōRSE is a leader in water-soluble emulsion technology for integrating functional ingredients into commercially available consumer packaged goods. Data from Headset recently found that MAJOR was the top selling cannabis beverage brand in the U.S. during Q1 2021. The Company began selling MAJOR beverages in October 2021.

On July 20, 2021, the Company announced that the provisional cannabis dispensary license in Ohio for which the Company and its joint venture partner have a binding LOI to access, has become operational. As previously disclosed, the Company has a binding LOI with its joint venture partner to transfer ownership of the license. Once the licensed entity has been operational for 12 months, the Company and its joint venture partner may apply to the Ohio Board of Pharmacy for a change in ownership of the provisional license.

On July 28, 2021, the Company announced that it has signed an agreement with Agtech PA LLC (“Agtech”) to exclusively produce and sell Wynk THC seltzers (“Wynk”) in Arizona. Vext began selling Wynk beverages in October 2021.

The Company made additional loans during the quarter that now total \$555,000 for working capital per the LOI to APP 1803. The LOI is for the right to purchase the Columbus Dispensary that began operating in July.

\$15,000 was loaned to APP1804 for operating expenses related to securing leases of property that is required for application of additional dispensary licenses in Ohio.

	September 30, 2021	December 31, 2020	Total
APP 1803, LLC			
Contributions	\$ 1,200,000	\$ 2,800,000	\$ 4,000,000
Working capital	570,000	—	570,000
Deposit for license	70,000	—	70,000
Interest	155,463	—	155,463
	1,995,463	2,800,000	4,795,463
APP Pharms, LLC			
Startup loan	—	500,000	500,000
Working capital	353,147	—	353,147
	353,147	500,000	853,147
Total	\$ 2,348,610	\$ 3,300,000	\$ 5,648,610

COMPANY OVERVIEW

The Company was incorporated in British Columbia, Canada on December 11, 2015, and its head office are located at 2250 – 1055 West Hastings Street, Vancouver, BC, Canada, V6E 2E9. On May 13, 2019, the Company commenced trading on the Canadian Securities Exchange (“CSE”) under the symbol “VEXT”. On July 12, 2019, the Company commenced trading on the OTCQX Best Market under the ticker symbol (OTCQX: VEXTF).

On December 31, 2018, the Company closed a share exchange agreement where it acquired all the issued and outstanding shares of New Gen Holdings Inc. (“New Gen”) in exchange for certain shares of the Company. New Gen was incorporated in the State of Nevada on July 8, 2014 and in 2016, changed the state of incorporation to Wyoming. New Gen has several wholly owned subsidiaries for the purpose of providing exclusive operating services to Herbal Wellness Center Inc. (HWC) and Organica Patient Group (Organica), not-for-profit companies that hold licenses to cultivate, extract, and dispense connoisseur-grade cannabis brands and cannabis-related products in Arizona. New Gen manages the activities of its operating subsidiaries and has done so since incorporation.

The Company is an agricultural technology, services and property management company utilizing a full vertical integration business model to oversee and execute all aspects of cultivation, extraction, manufacturing (THC and CBD cartridges, concentrates, edibles), retail dispensary, and wholesale distribution of high margin cannabis THC and hemp CBD products. The Company currently provides these management and marketing services in Arizona to two licensed dispensaries. The Company has also entered into management agreements, operating agreements, investments, or non-binding letters of intent at the date of this MD&A in Kentucky, Nevada, Hawaii, California, Ohio, and Oklahoma. The Company has developed proven and sought after standard operating procedures (SOPs) to produce a full line of branded flower, Vapen branded THC and CBD distillates, concentrates, extracts, and edibles.

The Company has built and operates a service business for cannabis cultivation and processing located in the State of Arizona. Products produced under contract are sold through Herbal Wellness Center (“HWC”) and Organica Patient Group Medical Marijuana Dispensary (“Organica”), both licensed not-for-profit dispensaries located in Phoenix, Arizona. In other jurisdictions, the Company will provide SOPs and extraction expertise to partners pursuant to operating agreements. Products produced from these facilities will be branded as “Vapen”. The Company may assist in opening retail dispensaries where appropriate. The model minimizes the capital needed to enter new markets by avoiding, where appropriate, the costs and time associated with licensing and acquiring real estate. The business model provides both near term return on invested capital and minimized lead time to market.

The Company’s multi-state operations encompasses medical and adult-use cannabis and CBD products and services, including cultivation, processing, product development, and wholesale and retail distribution. Cannabis products include flower and trim, products containing cannabis flower and trim (such as pre-rolls), cannabis infused products, and products containing cannabis extracts (such as cartridges, concentrates, wax products, oils, tinctures, topical creams, and edibles). CBD products include tinctures, lotions, balms, cartridges, and other delivery systems.

The Company will enter new markets with limited capital risk, leveraging its operational expertise and brand strength. As a leader in the Arizona market, the Company is now monetizing both its manufacturing, cultivation and distribution expertise. The Company has negotiated joint ventures, management agreements and operating agreements in multiple states, most of which have commenced production at the date of this MD&A. The Company continues to grow by reinvesting its net profits back into the business.

Competitive strengths:

Product Development, Branding and Standard Operating Procedures (“SOPs”): The business commenced in Arizona, where the Company entered the market to provide cultivation, extraction and manufacturing, support for retail and wholesale distribution for high margin cannabis THC and hemp CBD through HWC. The Vapen brand is widely recognized throughout the State of Arizona.

The Company’s established SOPs provide consistency in product quality whether flower, extracts or edibles. Industry participants have sought out these capabilities, thus enabling a rapid expansion into other markets, many without the inherent time and costs associated with either direct license acquisition or the acquisition of existing operations. For this reason, the Company’s footprint is expanding rapidly with minimal capital requirements. The Company may also seek out attractive acquisitions of existing operations that are accretive.

The Company’s established operations in Arizona are positioned for continued growth and with the passage of Proposition 207 legalizing cannabis for adult use, the Company is already handling increased demand.

Licensing SOPs and Acquisitions: The strategy is to identify opportunities where the Company can deliver its SOPs to a rapidly expanding national and international market, where medical and recreational markets are converging and where the ability to penetrate both retail and wholesale markets effectively with the Vapen brand is quantifiable. Secondly, the Company seeks out partners for joint ventures and management agreements who have strength in cultivation, licenses, and real estate to support its extraction capabilities for both high margin cannabis THC and hemp CBD.

High Quality Cannabis and CBD Products: The Vapen Clear THC high quality solvent-free concentrates include daytime (sativa), afternoon (hybrid), and nighttime (indica) products, offered with multiple and convenient delivery options. Vapen extracts include high quality products produced from premium biomass. Vapen Clear THC products can be produced from any cannabis biomass thus complementing state-by-state expansion plan without compromising quality.

Vapen CBD and Pure Touch Botanicals branded products complement the Vapen brand and facilitate multi-state expansion plans.

Edibles produced under the Vapen Kitchens Brand consist of Vapen Clear infused products, THC chocolate bars, THC syrup, THC snacks, candies, and gummies. Vapen branded products have earned industry-wide recognition.

Management Team: The Vext management team possesses expertise in the cannabis industry, finance, capital markets, regulations, operations, project management, and marketing. This team has proven its ability to grow and scale companies, skills that have been inherited from the experience gained by the team over many years.

Replicable Processes and Scalability: The Company’s production processes are replicable and scalable, resulting in consistent quality and taste across all the Company’s products. SOPs utilized in the Arizona operation are being deployed in other states under various agreements.

Growth Strategies and Strategic Priorities:

Growth of Core Arizona Business: The company continues to focus on looking for opportunities for further expansion in Arizona as evidenced by the acquisition of the Eloy property, which when fully built out, will effectively triple the Company’s cultivation footprint. Focus also remains on limited license markets for expansion as evidenced by the Ohio dispensary LOI.

Joint Ventures and or Management Services Agreements: The Company continues to support the joint venture and management service agreements and they are making progress operationally and commercially. The Company will continue to focus on growing the Vapen Brand footprint in these markets.

DESCRIPTION OF BUSINESS AND OVERALL PERFORMANCE

The Company began operations in the State of Arizona, through its operating subsidiary, New Gen Holdings Inc. (New Gen), and subsidiaries. The Company was incorporated on December 11, 2015. New Gen was incorporated in the State of Nevada on July 8, 2014. New Gen has multiple subsidiaries for the purpose of providing operating services for not-for-profit cannabis companies that hold licenses to cultivate, extract, infuse and dispense cannabis products in Arizona.

Vext operates under management agreements, joint ventures, joint operation, investments or service agreements in Arizona, Kentucky, Ohio, Oklahoma, Nevada, and California.

On April 6, 2020, the Company acquired RDF Management, LLC and Firebrand, LLC, Arizona based companies, in order to provide exclusive services for the management, administration and operation of Organica Patient Group, Inc. (“Organica”), an Arizona not for profit corporation, which was issued and holds in good standing, a Medical Marijuana Dispensary Registration Certificate, by the Arizona Department of Health Services in the State of Arizona and certain intangible assets (collectively the “Transaction”).

Vext began its expansion in 2019 into other markets as summarized elsewhere in the MD&A.

Summary of Operations

For nine months ended September 30, 2021, the Company had revenue of \$27,935,765 a gross profit of \$12,478,415 and a gross profit margin of 44.7%. Comparatively, for the nine months ended September 30, 2020, the Company had revenue of \$18,784,469, gross profit of \$6,884,918, and a gross profit margin of 36.7%.

For the comparative quarters, the margin difference is attributed to additional management and service billings reflecting the addition of the RDF acquisition and the passage of Proposition 207 which established adult use cannabis sales in January 2021. The company was also able to obtain additional cultivation facilities to support increased demand. RDF and Firebrand have contributed to increased amortization expenses related to new equipment being used and amortization of the management service agreement and the Firebrand brand name. Additional equipment was purchased and began being used in production in June 2021 as part of the expanded extraction, kitchen, and fulfillment facilities.

Arizona Operations:

The Company’s services are provided individually by operating subsidiaries pursuant to ten-year renewable management services agreements providing, among other things, employee leasing services, physical plant for cultivation and extraction of cannabis and derivative products, agricultural technology and research services, and related management and administrative services.

HWC and Organica sell products on a retail basis to customers holding a valid medical marijuana card and on a wholesale basis to other licensed cannabis operations throughout the State of Arizona. With the passage of Proposition 207, the State of Arizona has legalized adult use. The adult use program licenses were granted to HWC and Organica on January 22, 2021 and both locations began selling adult use on January 28, 2021.

HWC and Organica are independent from the Company and operate pursuant to Arizona law as not-for-profit corporations. The Company’s subsidiaries provide services to HWC and Organica enabling both to conduct their respective businesses. With the passage of Proposition 207, the dispensaries can be acquired and operated as a for profit entity. The Company is anticipating clarification on the process in 2021 and completing the conversion if advantageous to the shareholders.

Organica Patient Group, Inc.

On April 6, 2020, the Company acquired RDF Management, LLC (“RDF”) and Firebrand, LLC (“Firebrand”), Arizona based companies, in order to provide exclusive services for the management, administration and operation of Organica Patient Group, Inc. (“Organica”), an Arizona not for profit corporation, which was issued and holds in good standing, a Medical Marijuana Dispensary Registration Certificate, by the Arizona Department of Health Services in the State of Arizona and certain intangible assets (the “Organica Transaction”). Organica has been operational in the Arizona market since 2013, with its retail dispensary located and operational in Chino Valley, Arizona, which has been relocated to north Phoenix, and its offsite cultivation facility located in and operational in Prescott Valley, Arizona. Organica cultivates and produces medical & recreational marijuana and medical & recreational marijuana products which are sold and distributed on a retail and wholesale basis in State of Arizona.

RDF Management, LLC

Organica entered into a management services agreement with RDF effective as of March 20, 2020. Pursuant to the terms of the agreement, RDF agreed to provide services to Organica in connection with the operation and management of certain licensed medical or recreational marijuana cultivation, infusion kitchen and extraction facilities or dispensaries. As noted above, the Company acquired RDF on April 6, 2020. With the acquisition of RDF, New Gen Holdings began providing services directly to Organica. The term of the agreement is 10 years and automatically renews. New Gen Holdings, Inc.’s subsidiaries receive payments for management services and support of the dispensary and cultivation facilities.

Herbal Wellness Center

Herbal Wellness Center has contracted with New Gen Holdings, Inc. for management services, support of retail, cultivation operations and securing supplies. The contract is for 10-year terms and renews automatically.

On December 31, 2018, the Company completed a transaction pursuant to which New Gen Holdings, Inc. became a wholly owned subsidiary of the Company. New Gen Holdings, Inc. was incorporated in the State of Nevada on July 8, 2014 and in 2016, changed the state of incorporation to Wyoming. New Gen Holdings, Inc. has several wholly owned subsidiaries for the purpose of providing exclusive operating services to HWC and Organica. New Gen Holdings, Inc. manages the activities of its operating subsidiaries and has done so since its incorporation.

On December 31, 2019, the Company and HWC entered into a promissory note, whereby \$2,933,957 was re-classified from accounts receivable into an interest-bearing note. The note bears an interest rate of 10% per annum, beginning on January 1, 2020. As at September 30, 2021, the remaining outstanding balance is \$1,082,874 plus accrued interest

As at December 31, 2020, \$1,605,970 was drawn by HWC from a line of credit secured promissory note. As at September 30, 2021, \$4,439,835 was drawn by HWC from a line of credit secured promissory note.

During the year ended December 31, 2020, \$2,168,383 was included as part of the Organica line of credit. As at September 30, 2021 \$1,864,735 was drawn by Organica from a line of credit secured promissory note.

Joint Ventures and Joint Operations

None of the Company's joint ventures or joint operation are with related parties of the Company.

STATE	FOOTPRINT	VAPEN PRODUCTS IN MARKET	PRODUCT TYPE	VEXT RELATIONSHIP	VEXT ECONOMIC INTEREST	CURRENT STATUS	EXPECTED SHORT TERM DEVELOPMENTS
Ohio	Processing and/or Wholesale	Yes	THC	Joint Operation	NA	Vapen actively being sold at dispensaries in the market	Expanding SKUs and on-shelf presence
	Retail	NA	NA	LOI	NA	Current license holder received Certification of Operation and is fully functional	Vext and current license holder may apply for change in ownership in Q2 2022
Kentucky	Processing and/or Wholesale	Yes	CBD	Joint Venture	50%	Operating and selling wholesale product	Working on recurring base load supply contracts
Nevada	Processing and/or Wholesale	Yes	THC	Service Agreement	Licensing Fee	Vapen actively being sold at dispensaries in the market	Expanding on-shelf presence for Vapen brand
Oklahoma	Processing and/or Wholesale	Yes	THC	Joint Venture	25%	Expanding SKUs and on-shelf presence	Second harvest from outdoor grow
California	Processing and/or Wholesale	Yes	THC	Joint Operation	~50%	Vapen actively being sold at dispensaries in the market	Expanding on-shelf presence for Vapen brand

Vapen Oklahoma, LLC

Vapen, LLC entered into an operating agreement dated effective March 5, 2020 with Texoma Processing and Extraction, LLC ("TPE") to form a joint venture, Vapen Oklahoma, LLC ("Vapen OK"). Vapen OK conducts business in Oklahoma. Operations commenced in the second quarter of 2020. Vapen, LLC is a minority member of Vapen OK, owning 25%, with TPE owning the remaining 75% interest. Both TPE and Vapen, LLC have agreed to contribute equal amounts of capital to cover the initial expenses and assist in operations. Pursuant to the terms of the agreement, Vapen, LLC has agreed to provide equipment, training, SOPs, marketing and branding, and working capital loans as needed for startup. TPE has agreed provide the licensing, facilities, and working capital for startup as needed. Members have agreed to provide Vapen OK with certain assets in order to enable Vapen OK to operate a cannabis extraction and kitchen facility and other business (TPE will provide physical space and Vapen, LLC will provide equipment). Each of Vapen, LLC and TPE will enter into a loan agreement with Vapen OK with respect to such party's contribution to the joint venture. Vapen, LLC has agreed to license the Vapen brand to Vapen OK for Vapen OK to utilize during the term of the joint venture, and Vapen OK will be able to utilize the Vapen brand, without any licensing fees. All advances to Vapen OK must be repaid before there is any distribution to the joint venture members. As at September 30, 2021, the Company loaned Vapen OK \$877,426 for working capital. The working capital loan is interest free.

Vapen Kentucky, LLC

Vapen, LLC entered into an operating agreement dated effective February 1, 2020 with Emerald Pointe Hemp, Inc. ("EPH") and formed a joint venture, Vapen Kentucky, LLC ("Vapen KY"). Vapen KY conducts business in Kentucky. Operations commenced in the first quarter of 2020. Pursuant to the terms of the agreement, Vapen, LLC will supply equipment, training, SOPs, and working capital for startup as needed. EPH will supply building, licensing, access to biomass from its existing farming operations and working capital for startup as needed. Products will primarily be sold through wholesale distribution channels worldwide. Each party owns 50% of Vapen KY and shares in net profits on a 50/50 basis. Both members have agreed to contribute equal initial capital contributions. Funding arrangements also include a pre-operational budget and an annual operating budget. Each member can designate an individual to be on the board of managers (which exercises all powers of Vapen KY). No action of the managers or Vapen KY shall require member approval. All advances to Vapen KY must be repaid before there is any distribution to the joint venture members. As at September 30, 2021, the Company loaned Vapen KY \$1,300,520 for working capital. The working capital loan is interest free.

Happy Travels, LLC

On June 10, 2020, Vapen, LLC entered into a joint operation agreement with Green Goblin Inc. (GG) to operate Happy Travels, LLC (“Happy Travels”). Happy Travels conducts business in San Diego, California. Vapen and GG will utilize Happy Travels and its commercial manufacturing license to jointly operate a commercial cannabis manufacturing, extraction and kitchen facility in the state of California. Vapen is supplying equipment, training, SOPs and working capital as needed to Happy Travels. The title and rights to the equipment supplied by Vapen, LLC will remain with Vapen, LLC. GG has agreed to supply the building, licensing, and access to biomass to Happy Travels. The Company and GG have equal voting rights. Vapen, LLC is entitled to 50% of all profits received by the joint operation and has agreed to cover 50% of all losses. However, GG owns 100% of Happy Travels (Vapen, LLC owns 0%). In the event of a sale of Happy Travels or substantially all of the assets of Happy Travels, including a change in the membership of Happy Travels, Vapen, LLC will be compensated as if it has a 45% interest in Happy Travels. Vapen, LLC has agreed to provide Happy Travels working capital loans, and Happy Travels’ repayment obligations will begin when Happy Travels attains \$400,000 in working capital. All revenues and profits will be shared equally between Vapen, LLC and GG. All advances to Happy Travels must be repaid before there is any distribution to the joint venture members. The term of the initial joint operation will be three years, with automatic successive renewal terms of additional two-year periods. As at September 30, 2021 \$306,383 was advanced to Happy Travels, and \$24,000 is the Company’s portion of funds Happy Travels advanced Green Goblin.

Investments, Management Agreements, and Non-Binding Letters of Intent

Las Vegas Wellness and Compassion, LLC

Vapen, LLC entered into a management services agreement and intellectual property and commercialization agreement with Las Vegas Wellness and Compassion, LLC (“LVWC”) effective as of September 6, 2019. Vapen, LLC earns a participation fee (the “Participation Fee”) equal to 33% of the net income of LVWC as calculated in accordance with the management services agreement, with such Participation Fee to be paid on an annual basis. The management services agreement has a five-year term and is renewable for consecutive five-year terms. The intellectual property and commercialization agreement sets out the trademarks for all licensed products to LVWC and from which LVWC will derive revenue and from which Vapen, LLC will receive its Participation Fee.

Legacy Ventures Hawaii, LLC

On August 22, 2019, Vapen CBD, LLC, a subsidiary of Vapen, LLC, entered into a subscription agreement to purchase 350,000 Class B Units of Legacy Ventures Hawaii, LLC (“Legacy”) for a total purchase price of \$350,000, representing a 12.28% membership interest in Legacy. Legacy was formed to make an investment in Archipelago Ventures Hawaii, LLC. (“Archipelago”). As of September 30, 2021, the Company has invested additional funds for a total of \$425,350 in its membership interest in Legacy. Archipelago was formed as a partnership between Arcadia Bio Science Inc. and Legacy to engage in the cultivation and production of Hemp related products in Hawaii. Vapen CBD, LLC was issued 175,000 Class A Units (19.62% membership) of Legacy as of June 30, 2021 as consideration for providing services related to Archipelago’s business. At September 30, 2021 the Company determined that its investment in Legacy Ventures Hawaii was impaired due to delays created from COVID restrictions on Molokai (Hawaiian Islands) and changes within the regulatory positions of Hawaii in regards to CBD cultivation and processing. As a result, the Company chose to write down 50% of its investment, \$212,675, in Legacy Ventures Hawaii while it continues to retain its 19.62% ownership interest. The Company will reevaluate this investment at year end.

Appalachian Pharms Processing, LLC

On March 30, 2020, the Company’s wholly owned subsidiary, Vapen, LLC (“Vapen”), entered into a non-binding letter of intent (the “LOI”) with Appalachian Pharms Processing, LLC (“App Pharms”) to form a joint venture in Ohio (“APP”) related to the manufacturing, production and sale of medical cannabis (marijuana) products in Ohio, pursuant, and subject to, applicable Ohio state law.

On March 30, 2020, Vapen agreed, and subsequently advanced to App Pharms, \$500,000 in two equal installments of \$250,000 on April 1, 2021, and April 6, 2021, for the exclusive purpose for the manufacturing and production of cannabis products as well as associated expenses. In addition to the initial loan, Appalachian Farms Processing has subsequently been loaned \$343,147 for additional working capital that has been used for raw material and consumable materials. As at September 30, 2021, total funded to APP as a note receivable was \$853,147.

On October 18, 2021, the Company announced that it received approval from the State of Ohio and been granted ownership of the operating manufacturing facility in Jackson, Ohio. The Company has a 37.5% ownership in App Pharms.

APP1803 (Appalachian Pharms Processing 1803), LLC

On March 15, 2021, the Company entered into an LOI with APP1803 to acquire an option for a dispensary license in Ohio. Through a Vext subsidiary, the Company will have a 50% economic interest and a 48% ownership interest in the license. Vext’s total contribution for the option is \$4 million.

Per the LOI, Vext and APP1803, has executed a convertible loan agreement. The convertible loan agreement is expected to transfer the ownership of the license, per Ohio State regulations in 2022. Vext has fully funded its obligation per the LOI. In addition to the original payment of \$4 million, the Company has also advanced an additional payment of \$70,000 for license fees, a further \$555,000 in working capital to APP1803. Including accrued interest of \$155,463, total amount of funded to APP1803 as a note receivable as at September 30, 2021, was \$4,795,463. Associated delayed funding fees at the rate of 10% have been paid.

Vext has loaned to APP1804 \$15,000 to fund leases of potential dispensary locations in Ohio. The locations are required to submit applications for new dispensary licenses within Ohio. The agreement with APP1804 for new licenses, if awarded, where Vext will have a 50% economic interest and a 48% ownership.

The members of App Pharms and APP1803 are essentially the same. They are two separate LLCs within the State of Ohio for the purpose of ownership of the separate cannabis licenses. Interest on the Loan Agreements accrues at the rate of 10% per annum if not converted. The Loan Agreements mature 30 months from the effective date of the respective Loan Agreement.

The Company, through Vapen, funded the Loan Agreements from the Company’s internally generated working capital. The Loan Agreements are secured against the processing license held by App Pharms and the assets of APP1803.

	September 30, 2021	December 31, 2020	Total
APP 1803, LLC			
Contributions	\$ 1,200,000	\$ 2,800,000	\$ 4,000,000
Working capital	570,000	—	570,000
Deposit for license	70,000	—	70,000
Interest	155,463	—	155,463
	1,995,463	2,800,000	4,795,463
APP Pharms, LLC			
Startup loan	—	500,000	500,000
Working capital	353,147	—	353,147
	353,147	500,000	853,147
Total	\$ 2,348,610	\$ 3,300,000	\$ 5,648,610

Competitive Advantages:

Brand Strength:

The Company has developed and supports the Vapen brand of products. The products are recognized for their high quality and competitive price structure. In Arizona and Ohio, the Vapen brand is available in the majority of dispensary locations.

Vapen branded products encompass edibles, concentrates and extracts. Vapen's social media following and activity is extensive and has helped propel the brand's recognition and growth.

Distribution Channels:

The Company has a well-developed distribution process at both retail and wholesale levels in Arizona. The Vapen brand is carried by most of the dispensaries in that market. Joint ventures as noted elsewhere in the MD&A will further expand the distribution capability of the Company as it moves into new markets. The cost of expanding distribution is shared with partners in each location.

Supply Chain:

The Company has a well-established supply chain. The Company uses multiple suppliers, both international and domestic. Suppliers are proven and reliable to meet the needs of the Company.

Financial Strength:

The Company has a proven track record of operating profitable cannabis companies, providing access to capital markets to support growth and expansion into different geographic markets.

HIGHLIGHTS FOR THE THREE MONTHS ENDED SEPTEMBER 30, 2021

The Company has reviewed its financial position and results of operations for the three months ended September 30, 2021 with a view to assessing an impact that the novel corona virus known more particularly as COVID-19 has had or will have on the business going forward. Although there can be no assurance that there will not be an impact on the Company's financial position or operations (see Risk Factors – COVID-19), at the date of this MD&A, the following determinations have been made by management:

- a) There has been no inherent loss in the carrying value of the Company's assets as of September 30, 2021, beyond the write down of the investment in Legacy Ventures discussed previously. Management is of the opinion that both its current and long-term assets are fully collectable and or realizable at their recorded values.
- b) The Company has no obligations to third parties which have or will require renegotiation at the date of this MD&A
- c) Although there can be no assurances given with respect to future unknown events (See Risk Factors - COVID-19), the Company's outlook for 2021 remains on target. Construction delays have slowed initiation of operations in certain markets. These delays are being reflected in internal planning tools for revenue expectations in 2021 and were not caused by the COVID-19 outbreak.
- d) The Company has funded all its currently planned expansion programs in the markets referred to in this MD&A and accordingly the capital requirements to operate in these expanded markets has been met. Management is particularly conservative with the application of its current liquid assets and therefore the 2021 expansion plans are not dependent upon additional outside capital. Continued growth will of course be determined by market forces outside the control of the Company.
- e) To date, the Company has been deemed an essential service in all its markets and therefore continues to operate without interruption or suspension. That said, management is taking all necessary preventative actions to protect and safeguard its employees and customers from the effects of COVID-19.

Use of Available Funds & Business Objectives and Milestones from November 2020 Offering

The net proceeds of the offering are currently intended to be used for corporate expansion projects and general corporate purposes. Specifically, the Company expects to use the net proceeds of the Offering for the following purposes:

Project	Timeline	Milestone	Allocation of Net Proceeds
Phase IV Buildout of Cultivation Facility	Completed	Facility build-out and additional growing rooms in existing cultivation building located in Phoenix, Arizona	\$3,000,000
Organica Expansion	Completed	New dispensary relocated to Phoenix in conjunction with the acquisition of the management service agreements for Organica Patient Group, Inc.	\$1,000,000
General corporate purposes	Completed	n/a	\$1,280,000
		Total	\$5,280,000

Use of Available Funds & Business Objectives and Milestones from February 2021 Offering

Project	Timeline	Milestone	Allocation of Net Proceeds
Acquire Cultivation Facilities	Completed	Acquire Cultivation Facilities in Phoenix and Prescott Arizona.	\$3,000,000
Acquire new Cultivation Facilities	Completed	Acquire new Cultivation building and facilities which, when built, out will triple our current cultivation capacity	\$4,300,000
Build out newly acquired facilities	Completed	Build out new cultivation facilities	\$8,000,000
General corporate purposes	Next 6 Months	n/a	\$2,000,000
		Total	\$17,300,000

SELECTED QUARTERLY INFORMATION

The following financial data was derived from the Company's financial statements for each of the Company's most recent seven completed financial quarters:

EBITDA and Adjusted EBITDA

The Company defines EBITDA and Adjusted EBITDA as per the table below. It should be noted that these performance measures are not defined under IFRS and may not be comparable to similar measures used by other entities. The Company believes that these measures are useful financial metrics as they assist in determining the ability to generate cash from operations. Investors should be cautioned that EBITDA and Adjusted EBITDA should not be construed as an alternative to net earnings or cash flows as determined under IFRS. The reconciling items between net earnings, EBITDA, and Adjusted EBITDA are as follows:

	2021 Q3	2021 Q2	2021 Q1	2020 Q4	2020 Q3	2020 Q2	2020 Q1
Revenue	\$ 9,399,700	\$9,375,774	\$9,160,291	\$ 6,409,489	\$7,951,648	\$6,736,723	\$4,096,098
Gross Profit	\$ 4,101,313	\$4,217,215	\$4,159,887	\$ 3,018,869	\$3,135,135	\$2,543,992	\$1,205,791
Gross Profit Margin (%)	43.6%	45.0%	45.4%	47.1%	39.4%	37.8%	29.4%
Operating Expenses**	\$ 3,131,207	\$2,424,766	\$3,020,810	\$ 1,892,153	\$1,722,161	\$1,987,595	\$2,176,811
Net Income (loss) after taxes	\$ 970,106	\$1,792,449	\$1,139,077	\$ 1,126,716	\$1,412,974	\$ 556,397	\$(971,020)
Interest (Net)	\$ 75,574	\$ (38,194)	\$ (13,876)	\$ (109,348)	\$ 63,917	\$ 75,658	\$ 44,833
Income Taxes	\$ 538,308	\$ 433,636	\$ 398,900	\$ 514,000	\$ —	\$ —	\$ —
Depreciation & Amortization	\$ 886,920	\$ 743,999	\$ 718,394	\$ 629,228	\$ 802,108	\$ 426,024	\$ 269,098
EBITDA	\$ 2,470,908	\$2,931,890	\$2,242,495	\$ 2,160,596	\$2,278,999	\$1,058,079	\$(657,089)
<i>Accretion</i>	\$ 785,192	\$ 208,946	\$ 58,399	\$ 36,589	\$ 37,542	\$ 25,354	\$ 26,134
<i>Share (Profit) / Loss on JVs</i>	\$ 2,602	\$ 102,938	\$ 303,157	\$ 127,627	\$ 76,747	\$ 253,908	\$ 62,520
<i>Share-based compensation</i>	\$ 171,479	\$ 220,410	\$ 424,953	\$ 243,554	\$ 86,790	\$ 461,926	\$ 87,406
<i>Office and General*</i>	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —	\$ 500,000
<i>Gain on derecognition of ROU</i>	\$ —	\$ (3,195)	\$ —	\$ —	\$ —	\$ —	\$ —
<i>(Gain)/Loss on Investment</i>	\$ 212,675	\$ —	\$ —	\$ —	\$ —	\$ —	\$ —
<i>(Gain)/Loss on asset disposal</i>	\$ (75,000)	\$ —	\$ —	\$ 77,987	\$ 82,531	\$ —	\$ 766
<i>Foreign Exchange</i>	\$ (29)	\$ 2,746	\$ 5,140	\$ (353,179)	\$ 18,738	\$ 132,616	\$ (126,347)
Adjusted EBITDA	\$ 3,567,827	\$ 3,463,735	\$ 3,034,144	\$ 2,293,174	\$ 2,581,347	\$1,931,883	\$ (106,610)
Total	\$ 10,065,706	2021		\$ 6,699,794	2020		

* Includes a one-time severance settlement with the former CFO, President, Corporate Secretary, and Director.

** Totals are for year to date for 2021 and for the complete year for 2020.

Quarter over quarter results may vary due to New Gen, the Company's wholly owned subsidiary, being a service and product supplier to cannabis companies, meaning that as product is received at New Gen from the supply chain, revenues from the customer companies will follow in that period. Revenues tend to decrease in periods with lower procurement of raw materials and supplies.

New Gen is primarily a service and product supplier with management services agreements in the State of Arizona servicing two not-for-profit licensed cannabis dispensaries, HWC and Organica. The Company's business outside of Arizona is conducted by way of either participating as a member of joint ventures or by way of investment in entities conducting business in selected markets. At the date of this MD&A, most of the Company's revenues have been historically generated from the Company's Arizona operations. During the three months ended September 30, 2021, the Company has utilized cash flows from operations and financings to invest in ventures outside the State of Arizona, which have not yet begun to generate significant revenues.

Therefore, comments made with respect to the quarterly results herein are focused on Arizona operations. Due to the nature of the business, revenues have been generated by the provision of products and services to its two customers in the State of Arizona. Cost of sales generally follow sales trends. Operating expenses have fluctuated due to one-time charges and/or adjustments that were made in part for continued IFRS compliance.

As reported above, the first quarter of 2020 reported losses compared to the other six disclosed quarters. These variations were the result of one-time charges to operating expenses, but not the result of any changes in buying patterns, changes in selling practices, the impact of competition, exchange rate impacts on purchases, input changes, production capacity or sales discounts. In the quarter noted, the Company reduced the management fees charged to HWC, in anticipation of the Organica acquisition. Other one-time charges in that quarter impacted operations. The Company has met and continues to meet its goals and milestones, utilizing its resources to efficiently maintain stable and predictable growth.

Financial Position as at September 30, 2021

The following discussion of the Company's financial position is based on the Company's consolidated statement of financial position as at September 30, 2021 and December 31, 2020 in comparison.

Current Assets

As at September 30, 2021, the Company had total current assets of \$31,977,985 (2020 – \$23,997,578). The current assets were made up of the following: cash of \$7,443,415 (2020 – \$1,745,381), accounts receivable of \$22,099,180 (2020 – \$17,224,397), inventory of \$338,607 (2020 – \$857,317), due from related parties - current of \$537,151 (2020 - \$537,151), prepaid deposits and other receivables of \$777,931 (2020 – \$1,566,145), notes receivable – current of \$451,319 (2020 – \$1,853,573), advances to joint ventures and operation of \$330,383 (2020 – \$69,013), and investment in sublease - current of \$Nil (2020 – \$144,601).

Accounts Receivable

The company's account receivable is comprised of balances owed by the dispensary operations. Prior to the acquisition of RDF Management, LLC and Firebrand, LLC, the accounts receivable was related to HWC, but now it includes Organica as well. The accounts receivable from both HWC and Organica are at 180-day terms. The growth in the balance represents the new Organica dispensary that opened in Phoenix, July 2020, and increased volumes. HWC made all of their scheduled payments during the quarter.

Non-current Assets

As at September 30, 2021, the Company's non-current assets were \$50,036,052 (2020 – \$31,457,083). Non-current assets are comprised of long term notes receivable of \$12,714,735 (2020 – \$7,024,110), investment in Legacy Ventures of \$212,675 (2020 – \$350,000), property, plant and equipment \$26,598,291 (2020 – \$12,457,565), investment in sub-lease \$Nil (2020 – \$432,287), investment in joint ventures \$1,248,447 (2020 – \$1,282,598), right-of-use asset \$236,217 (2020 – \$258,362), related party loans receivable of \$1,644,634 (2020 – \$1,644,634), and intangible assets \$7,381,052 (2020 - \$8,007,527).

Current Liabilities

As at September 30, 2021, the Company's current liabilities were \$8,745,804 (2020 – \$8,832,393). Current liabilities include the following: accounts payable and accrued liabilities of \$2,714,773 (2020 – \$2,572,975), loan payable of \$4,339,070 (2020 - \$4,165,034), current portion of notes payable of \$1,130,876 (2020 – \$920,828), current portion of RDF note payable of \$501,665 (2020 - \$948,750), current portion of lease liability of \$13,787 (2020 – \$156,694), due to Legacy Ventures Hawaii of \$Nil - (2020 - \$22,479) and income taxes payable of \$45,633 (2020 – \$45,633).

Non-current Liabilities

As at September 30, 2021, the Company's non-current liabilities were \$15,525,863 (2020 – \$10,309,148). Non-current liabilities include the following: Long-term portion of lease liability of \$255,559 (2020 – \$701,810), long-term portion of RDF Acquisition note payable of \$4,262,275 (2020 – \$4,529,575), loan payable of \$4,624,186 (2020 – \$64,763), and deferred tax liabilities of \$6,383,844 (2020 – 5,013,000).

Shareholders' Equity

As at September 30, 2021, the Company had shareholders' equity of \$57,742,370 (2020 – \$36,313,120).

Working Capital Position

As at September 30, 2021, the Company's working capital position was \$23,232,181 compared to \$15,165,185 as at December 31, 2020.

Financial Results of the Operation for the Three Months Ended September 30, 2021

	For the Three Months Ended		\$	%
	September 30, 2021	September 30, 2020	Change	Change
REVENUES	\$ 9,399,700	\$ 7,951,648	\$1,448,052	18.2%
COST OF SALES	(5,298,387)	(4,816,513)	(481,874)	10.0%
GROSS PROFIT	\$4,101,313	\$3,135,135	\$966,178	30.8%
OPERATING EXPENSES	(2,656,203)	(1,635,937)	(1,020,266)	62.4%
Share of profit (loss) on Joint Ventures	(2,602)	(76,747)	74,145	(96.6%)
Gain /(Loss) on Asset Disposal	75,000	(82,531)	157,531	(190.9%)
Loss on Investment	(212,675)	—	(212,675)	100.0%
Foreign exchange Gain / (Loss)	29	(18,738)	18,767	(100.2%)
Interest income	203,552	91,792	111,760	121.8%
Net income (loss) before taxes	\$1,508,414	\$1,412,974	\$95,440	6.8%
Income tax expense	(538,308)	—	(538,308)	100.0%
Net income (loss) after taxes	\$970,106	\$1,412,974	(\$442,868)	(31.3%)
Unrealized gain on foreign exchange translation	(109,872)	21,292	(131,164)	(616.0%)
Total comprehensive income (loss)	\$860,234	\$1,434,266	(\$574,032)	(40.0%)

The following discussion of the Company's results of operations is based on its consolidated financial statements for the three months ended September 30, 2021 compared to the comparative period September 30, 2020.

The Company's revenues from operations were \$9,399,700 for the three months ended September 30, 2021, compared to \$7,951,648 for the three months ended September 30, 2020, an increase of \$1,448,052 or 18.2%. The increase was attributable to increases in demand from HWC, and the addition of the Organica dispensary management agreement, one-time billings for packaging material setup costs, and an increase in management fees related to the adult use initiative passing and acquisition of more cultivation facilities.

Management fees for the three months ended September 30, 2021 were \$1,350,000 compared to \$1,200,000 for the three months ended September 30, 2020, an increase of \$150,000 or 13%.

Professional services revenue for the three months ended September 30, 2021 was \$2,352,062 compared to \$2,052,578 for the three months ended September 30, 2020, an increase of \$299,484 or 15%. The increase was related to the increased demand at HWC and Organica.

Product sales revenue during for the three months ended September 30, 2021 was \$3,244,440 compared to \$3,408,245 for the three months ended September 30, 2020, a decrease of \$(163,805) or (5)%. The decrease in product sales relates to better management of supply chain and the standardization of product packaging related to rework for the adult use passage.

Equipment leasing revenues for the three months ended September 30, 2021 was \$2,223,548 compared to \$1,350,696 for the three months ended September 30, 2020, an increase of \$872,852 or 65%. The increase is related to build out of the manufacturing lab and kitchen and on-going operations at the Herbal Wellness Center facility. The Company passes its equipment leasing costs through to the not-for-profits; (HWC and Organica) on a cost-plus basis that is based upon going commercial rates.

Property leasing revenues for the three months ended September 30, 2021 was \$229,650 compared to \$(59,871) for the three months ended September 30, 2020, an increase of \$289,521 or 484%. This increase is due to timing of assets secured by New Gen Holdings and being placed into service, and billing to HWC or Organica under the terms of the three-year notes.

Total cost of sales for the three months ended September 30, 2021 was \$5,298,387 compared to \$4,816,513 for the three months ended September 30, 2020, an increase of \$481,874 or 10%. The cost of sales increase resulted from the following:

- **Cost of Goods Sold related to Product Sales** decreased from \$2,603,465 (2020) to \$2,378,440 (2021) for a total decrease of \$(225,025) or (9)%, the change is related to the packaging rework for child protection, standardization and the ability to use uniform packaging in all markets.
- **Salaries related to Professional Services** increased from \$1,856,835 (2020) to \$2,229,736 (2021) a total of \$372,901, an increase of 20% due to relocation of Organica dispensary into the Phoenix Metro area and expansion of outdoor cultivation, and increased production within the indoor cultivation.
- **Property, plant, and equipment costs** increased from \$21,778 (2020) to \$50,762 (2021) a total of \$28,984, an increase of 133% due to the finalization of building out the HWC indoor cultivation and processing center.
- **Amortization cost** increased from \$334,435 (2020) to \$639,449 (2021) a total of \$305,014, an increase of 91%. The increase is related to increased amortization following capital asset acquisition to support growth in Arizona, JVs and Operating Agreements.
- **Gross profit** for the three months ended September 30, 2021 was \$4,101,313 compared to \$3,135,135 for three months ended September 30, 2020, an increase of \$966,178 or 31% over the comparative quarter. Revenues and gross profit increased between the comparative quarters as the Company added the new manufacturing facility and increased the production of cultivation and retail operations.

The Company's total operating expenses were \$2,656,203 for the three months ended September 30, 2021 compared to \$1,635,937 for the three months ended September 30, 2020, an increase of \$1,020,266 or 62%. This increase was primarily due to increased share based compensation, salaries and wages, property taxes and utilities.

CASH FROM ACTIVITIES

The following table summarizes the sources and uses of cash for the nine months ended September 30, 2021, and September 30, 2020:

	9/30/2021	9/30/2020
Cash provided by operating activities	6,927,486	1,723,763
Net cash (used in) investing activities	(21,447,236)	(5,119,913)
Net cash provided (used in) by financing activities	20,217,784	(1,206,100)
Net change in cash	\$ 5,698,034	\$ (4,602,250)

Operating Activities

During the nine months ended September 30, 2021, operating activities contributed \$6,927,486 of cash compared to \$1,723,763 in the comparative period, an increase of \$5,203,723. The cash flow improvement is attributable to an improvement in net income.

Additionally, with respect to accounts receivable, it should be noted that the Company charges its management services pursuant to the various management agreements when the services or supplies are delivered or procured. Cultivation and product preparation consumes approximately 120 days in the cycle, and since the cash available from the customers is derived from product sales at the dispensary level, the Company's accounts receivable has a longer than traditional payment cycle, usually averaging 180 days. This in no way affects the collectability of the accounts.

Investing Activities

During the nine months ended September 30, 2021, cash flows used by investing activities was \$21,447,236 compared to \$5,119,913 for the comparative period in 2020, an increase of \$16,327,323. The increase is a combination of increased purchases of land and equipment related to expansion in Arizona to support adult use and making the final payment to secure 50% interest in a license in Ohio that will result in a dispensary and a planned cultivation center.

Financing Activities

During the nine months ended September 30, 2021, cash flows provided by financing activities was \$20,217,784 compared to \$(1,206,100) cash used by financing activities for the comparative period in 2020, an increase of \$21,423,884 over the comparative periods. This increase is attributed to the prospectus offering of \$16,259,725, and private placement of \$1,225,078, and a \$4,769,741 increase of notes payable due to two property acquisitions.

LIQUIDITY AND CAPITAL RESOURCES

These consolidated financial statements have been prepared using International Financial Reporting Standards applicable to a going concern which assumes the Company will continue in operation for the foreseeable future and be able to realize its assets and discharge its liabilities in the normal course of business. The continuing operations of the Company are dependent upon the Company's ability to continue to earn adequate revenues from operations and to raise adequate financing. The Company intends to finance its future requirements through continued operations.

As at September 30, 2021, the Company had working capital of \$23,232,181 (December 31, 2020 - \$15,165,185) and retained earnings of \$21,317,913 (December 31, 2020 - \$17,416,282). There is uncertainty as the likely effects of the novel coronavirus ("COVID-19") outbreak which may, among other things, impact the Company's operations and ability to raise further financing. Management has assessed that this working capital is sufficient for the Company to continue as a going concern beyond one year.

RELATED PARTY TRANSACTIONS

Related parties and related party transactions impacting the consolidated financial statements not disclosed elsewhere in these financial statements are summarized below and include transactions with the following individuals or entities:

Key management personnel

Key management personnel include those persons having authority and responsibility for planning, directing and controlling the activities of the Company as a whole. The Company has determined that key management personnel consist of members of the Company's Board of Directors and corporate officers, including the Company's Executive Chairman, Chief Executive Officer, Chief Operating Officer, President, Chief Financial Officer, and Corporate Secretary.

Remuneration attributed to key management personnel for the three months ended September 30, 2021 and September 30, 2020, is summarized as follows:

	Three months ended September 30, 2021	Three months ended September 30, 2020
Share-based compensation	\$ 40,984	\$ 16,462
Salaries and wages included in cost of sales		
Jason Nguyen, Executive Chairman	106,173	97,404
Eric Offenberger, CEO, COO, and Director	65,769	49,327
Salaries, wages and commissions included in operating expenses		
Jason Nguyen, Executive Chairman	5,588	5,127
Eric Offenberger, CEO, COO, and Director	3,462	2,596
Consulting fees included in operating expenses:		
Denise Lok, Former CFO	—	5,637
Brian Cameron, Former Corporate Secretary	—	30,000
Vahan Ajamian, CFO	21,588	—
	\$ 243,564	\$ 206,553

Other related parties

Other related parties include close family members of the Company's Executive Chairman, former CFO, a company that is controlled by a Director.

Remuneration attributed to other related parties for the three months ended September 30, 2021 and September 30, 2020 is summarized as follows:

	September 30, 2021	September 30, 2020
Salaries and wages included cost of sales	\$ —	\$ —
Salaries, wages and commissions included in operating expenses	—	60,000
Consulting fees included in operating expenses	36,000	73,523
	\$ 36,000	\$ 133,523

Balances with related parties:

Due from related parties:

The current portion of balances due from related parties is as follows:

	September 30, 2021	December 31, 2020
Non-interest bearing, due on December 31, 2021 from Jason Nguyen, Executive Chairman	\$ 537,151	\$ 537,151

The non-current portion of balances due from related parties is as follows:

	September 30, 2021	December 31, 2020
Non-interest bearing, due on December 31, 2022 from Jason Nguyen, Executive Chairman	\$ 316,251	\$ 316,251
Non-interest bearing, due on December 31, 2023 from Jason Nguyen, Executive Chairman	1,328,383	1,328,383
	\$ 1,644,634	\$ 1,644,634

OUTSTANDING SHARE DATA

The following share capital data is current as at the date of this MD&A:

Number Outstanding		
Subordinate voting shares		68,558,624
Multiple voting shares*		681,540
Stock options		3,064,334
Warrants		34,581,638
Special advisory warrants		1,000,000

*One multiple voting share can be converted into 100 subordinate voting shares.

PROPOSED TRANSACTIONS

Other than disclosed in this MD&A, the Company does not have any other proposed transactions at this time.

CHANGES IN ACCOUNTING POLICIES INCLUDING INITIAL ADOPTION

The Company adopted all of the requirements of IFRS 16 Leases (“IFRS 16”) as of January 1, 2019. IFRS 16 replaces IAS 17 Leases. IFRS 16 applies a control model to the identification of leases, distinguishing between a lease and a service contract on the basis of whether the customer controls the asset being leased. For those assets determined to meet the definition of a lease, IFRS 16 introduces significant changes to the accounting by lessees, introducing a single, on-balance sheet accounting model that is similar to current finance lease accounting, with limited exceptions for short-term leases or leases of low value assets. Lessor accounting is not substantially changed. The Company choose to apply the effect of changes retrospectively with the cumulative effect of initially applying the standards recognized to retained earnings at the date of initial application which is January 1, 2019.

The following is the Company’s accounting policy for leases under IFRS 16:

At inception of a contract, the Company assesses whether a contract is, or contains, a lease by determining whether the contract conveys the right to control the use of an identified asset for a period of time in exchange for consideration. A right of use asset and lease liability is recognized at the lease commencement date. The right of use asset is initially measured at cost, which comprises the initial amount of the lease liability adjusted for any lease

payments made at or before the commencement date, plus any initial direct costs incurred and an estimate of costs to dismantle and remove the underlying asset or to restore the underlying asset or the site on which it is located, less any lease incentives received.

The right of use asset is subsequently depreciated using the straight-line method from the commencement date to the end of the lease term, including periods covered by an option to extend the lease if the Company is reasonably certain to exercise that option.

The lease liability is initially measured at the present value of the lease payments that are not paid at the commencement date. The lease payments are discounted using the implicit interest rate in the lease. If the rate cannot be readily determined, the Company's incremental rate of borrowing is used. The lease liability is measured at amortized cost using the effective interest method. It is remeasured when there is a change in future lease payments arising from a change in an index or rate, if there is a change in the Company's estimate of the amount expected to be payable under a residual value guarantee, or if the Company changes its assessment of whether it will exercise a purchase, extension, or termination option.

If a right-of-use asset is re-leased, the corresponding right-of-use asset is derecognized and an investment asset is recorded at the present value of the lease income not paid at the commencement date discounted using the implicit rate in the lease or the Company's incremental rate of borrowing.

The Company has elected not to recognize right of use assets and lease liabilities for leases for short-term leases that have a lease term of 12 months or less and leases of low-value assets. The Company recognizes the lease payments associated with these leases as an expense on a straight-line basis over the lease term.

As at September 30, 2021 the Company is no longer engaging in subleases due to recent acquisitions. All subleases have been terminated and the respective transactions have been relieved and closed effective September 30, 2021. The Company is still engaged in one lease presented by the ROU valued at \$236,217.

RISK MANAGEMENT AND FINANCIAL INSTRUMENTS

The fair value of the Company's accounts receivable, current notes receivable, advances to joint ventures, deposits and other receivables, and payables, approximate carrying value, due to their short-term nature. The carrying amounts of the long-term notes receivable and amount due from related parties' approximate fair value. The fair values of the investment in sublease, right of use asset, and lease liability have been recorded as discussed in the audited financial statements. The long-term loan payable is recorded at fair value as discussed in the audited financial statements. The Company's cash and investment in Legacy are measured at fair value under the fair value hierarchy based on Level 1 quoted prices in active markets for identical assets or liabilities.

The Company's financial instruments are exposed to certain financial risks, including credit risk, liquidity risk, interest rate risk, price risk, and currency risk.

Credit risk

Credit risk is the risk of an unexpected loss if a customer or third party to a financial instrument fails to meet its contractual obligations.

The Company is subject to credit risk on its receivables. As at September 30, 2021, the Company was dependent on two major customers from its consulting business segment. The majority of the Company's accounts receivable are from these two customers. The Company is of the opinion that it is not exposed to significant credit risk from these two customers as at September 30, 2021, as it continues to collect accounts receivable routinely. The company has no investments in asset-backed commercial securities.

The Company records an allowance for doubtful accounts related to accounts receivable that are considered to be non-collectible. The allowance is based on the Company's knowledge of the financial condition of its customers,

current business environment, customer and industry concentrations, and historical experience. To reduce credit risk, cash is only held at major financial institutions. The company has no allowance for doubtful accounts.

Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due.

The Company manages liquidity risk through its capital management. As at September 30, 2021, the Company had cash, accounts receivable and short-term notes receivable of \$29,993,914 to settle its current liabilities of \$8,745,804. Management believes the Company has sufficient funds to support ongoing operating expenditures and meet its liabilities as they fall due.

Market risk

Market risk is the risk of loss that may arise from changes in market factors such as interest rates, commodity and equity prices, and foreign exchange rates.

a) Interest rate risk

Interest rate risk is the risk the fair value or future cash flows of a financial instrument will fluctuate because of changes in market interest rates.

The Company does not hold any financial instruments with variable interest rates, and as a result, is subject to insignificant interest rate risk.

b) Price risk

The Company is not exposed to significant price risk as it does not hold investments in publicly traded securities.

c) Currency risk

The Company's expenditures are predominantly in U.S. dollars, and any future equity raised is expected to be predominantly in Canadian dollars. As at September 30, 2021, the Company had \$3,765,739 (CAD \$4,781,284) net financial assets denominated in Canadian currencies at an exchange rate of 0.78760 as at September 30, 2021. A 10% change in the foreign exchange rate between the U.S. dollar and the Canadian dollar would result in a change on approximately \$376,574 (CAD \$478,128) in other comprehensive income.

OFF-BALANCE SHEET TRANSACTIONS

The Company has not entered into any significant off-balance sheet arrangements or commitments.

SUBSEQUENT EVENTS

- On October 18, 2021, the Company announced that it had received approval to have ownership of a manufacturing operation in Ohio, through a 37.5% ownership interest in Appalachian Pharm Processing, LLC, an Ohio limited liability company ("APP"). In July 2022, the Company expects to apply to the Ohio regulators, through another affiliated joint venture partner (the "Joint Venture"), to transition an operating cannabis dispensary license to the Joint Venture. The combination of these acquisitions, once approved by the Ohio regulators and completed, will move the Company closer to vertical integration in Ohio, which is an attractive limited license state with the potential for a future transition into an adult-use market.
- On November 17, 2021, the Company announced that an affiliated entity (the "Affiliate") of Appalachian Pharm Processing, LLC, an Ohio limited liability company ("APP"), has received a Level I Cultivator provisional license (the "License") to be collocated at the APP facility at 16064 Beaver Pike, Jackson, Ohio (the "Facility"). The License, granted by the Ohio Department of Commerce, will enable the Affiliate to build-out an initial cultivation area of up to 25,000 square feet, with the potential to expand up to 50,000 square feet following further application and approval.
- Subsequent to the quarter ended September 30, 2021, there were no changes in stock options exercised, granted, or cancelled, no change in RSUs granted, or cancelled, and no warrants expired, 891,100 warrants were exercised at CAD\$0.64 each for a total of CAD\$570,304, no change to brokers' warrants expiring or being exercised.

MANAGEMENT'S RESPONSIBILITY FOR THE FINANCIAL STATEMENTS

The information provided in this report is the responsibility of management. In the preparation of these statements, estimates are sometimes necessary to decide of future values for certain assets or liabilities. Management believes such estimates have been based on careful judgments and have been properly reflected in the accompanying financial statements.

RISK AND UNCERTAINTIES

Uninsured or Uninsurable Risk

The Company may become subject to liability for risks against which it cannot insure or against which it may elect not to insure due to the high cost of insurance premiums or other factors. The payment of any such liabilities would reduce the funds available for the Company's usual business activities. Payment of liabilities for which the Company does not carry insurance may have a material adverse effect on its financial position and operations.

DESCRIPTION OF THE U.S. LEGAL CANNABIS INDUSTRY

In accordance with the Canadian Securities Administrators Staff Notice 51-352 (Revised) dated February 8, 2018 – Issuers with U.S. Marijuana-Related Activities ("CSA Notice 51-352"), below is a discussion of the current federal and state-level U.S. regulatory regimes in those jurisdictions where the Company is currently directly involved. In accordance with CSA Notice 51-352, the Company will evaluate, monitor, and reassess this disclosure, and any related risks, on an ongoing basis and the same will be supplemented, amended and communicated to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws or regulations regarding marijuana regulation.

Legal and Regulatory Matters

United States Federal Overview

In the United States, thirty-seven (37) states, Washington D.C. and Puerto Rico have legalized medical marijuana, and eighteen (18) states and Washington D.C. have legalized "adult use" or "recreational" marijuana. At the federal level, however, cannabis currently remains a Schedule I drug under the CSA. Under United States federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. As such, cannabis related practices or activities including, without limitation, the manufacture, importation, possession, use, or distribution of cannabis, remain illegal under United States federal law. Although federally illegal, the U.S. federal government's approach to enforcement of such laws has at least until recently trended toward non-enforcement. On August 29, 2013, the DOJ issued a memorandum known as the "Cole Memorandum" to all U.S. Attorneys' offices (federal prosecutors). The Cole Memorandum generally directed U.S. Attorneys not to prioritize the enforcement of federal marijuana laws against individuals and businesses that rigorously comply with state regulatory provisions in states with strictly regulated medical or recreational cannabis programs. While not legally binding, and merely prosecutorial guidance, the Cole Memorandum laid a framework for managing the tension between state and federal laws concerning state regulated marijuana businesses. However, on January 4, 2018, the Cole Memorandum was revoked by Attorney General Jeff Sessions, a long-time opponent of state- regulated medical and recreational cannabis. While this did not create a change in federal law, as the Cole Memorandum was not itself law, the revocation removed the DOJ's guidance to U.S. Attorneys that state-regulated cannabis industries substantively in compliance with the Cole Memorandum's guidelines should not be a prosecutorial priority. In addition to his revocation of the Cole Memorandum, Attorney General Sessions also issued a one-page memorandum known as the "Sessions Memorandum". The Sessions Memorandum confirmed the rescission of the Cole Memorandum and explained the rationale of the DOJ in doing so: the Cole Memorandum, according to the Sessions Memorandum, was "unnecessary" due to existing general enforcement guidance adopted in the 1980s, as set forth in the U.S. Attorney's Manual (the "USAM"). The USAM enforcement priorities, like those of the Cole Memorandum, are also based on the federal government's limited resources, and include "law enforcement priorities set by the Attorney General,"

the “seriousness” of the alleged crimes, the “deterrent effect of criminal prosecution,” and “the cumulative impact of particular crimes on the community”. While the Sessions Memorandum emphasizes that marijuana is a Schedule I controlled substance, and reiterates the statutory view that cannabis is a “dangerous drug and that marijuana activity is a serious crime”, it does not otherwise indicate that the prosecution of marijuana-related offenses is now a DOJ priority. Furthermore, the Sessions Memorandum explicitly describes itself as a guide to prosecutorial discretion. Such discretion is firmly in the hands of U.S. Attorneys in deciding whether or not to prosecute marijuana-related offenses.

Arizona Overview:

Arizona has authorized the cultivation, extraction and dispensing of medical marijuana products by licensed dispensaries located throughout the State. There are 130 licenses in the state which cover all categories of production and sale of cannabis and cannabis related products. In 2010, Arizona became the 14th state to legalize medicinal cannabis for adults over 21 under Proposition 205: the Arizona Medical Marijuana Act (AMMA). Arizona is one of the 37 states to have some form of medical marijuana law in place. The AMMA is used as an example for other states as an effective way to regulate a legal cannabis industry. In Arizona, the dispensaries operate as not-for-profit entities and engage with management companies to provide real estate rental, administrative, general management and advisory services, financing and logistics to medical marijuana businesses (the dispensaries) licensed under the provisions of the Arizona Medical Marijuana Act, A.R.S. Title 36, Section 28.1 (the “AMMA”) and to provide material support. These management companies exert considerable influence and control over not-for-profit dispensaries.

Medical Use

Arizona Medical Marijuana cardholders are entitled to purchase not more than 2.5 ounces of product every two weeks. Purchases are tracked by cardholder and all dispensaries are required to report cardholder sales to the state to ensure that cardholders do not exceed their allotted purchase amount. New Gen and its subsidiaries are in compliance with Arizona’s medical marijuana regulatory requirements and programs where applicable.

Adult Use

On November 3, 2020, Arizona voters passed Proposition 207, the “Smart and Safe Act”, allowing adults to possess up to 1 ounce (28 grams) of marijuana (with no more than 5 grams being marijuana concentrate). Possession and cultivation of cannabis for adult use became legal on November 30, 2020. State-licensed sales of adult use cannabis began January 22, 2021. New Gen and its subsidiaries are in compliance with Arizona’s adult use marijuana regulatory requirements and programs where applicable.

Regulatory Risks

The U.S. cannabis industry is highly regulated, highly competitive and evolving rapidly. As such, new risks may emerge, and management may not be able to predict all such risks or be able to predict how such risks may impact on actual results.

Participants in the U.S. cannabis industry will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional costs for corrective measures, penalties or restrictions of operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company. Further, the Company may be subject to a variety of claims and lawsuits. Adverse outcomes in some or all of these claims may result in significant monetary damages or injunctive relief that could adversely affect its ability to conduct its business. Litigation and other claims are subject to inherent uncertainties and management’s view of these matters may change in the future. A material adverse impact on the Company’s financial statements also could occur for the period in which the effect of an unfavorable final outcome becomes probable and reasonably estimable.

The U.S. cannabis industry is subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The marketability of any product may be affected by numerous factors

that are beyond the control of the Company and which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce the Company's earnings and could make future growth uneconomic. The industry is also subject to numerous legal challenges, which may significantly affect the financial condition of the Company and which cannot be reliably predicted.

The Company expects to derive most of its revenues from the U.S. cannabis industry, which industry is illegal under U.S. federal law (other than its business related to high CBD/low THC products, known as "hemp"). As a result of the conflicting views between state legislatures and the federal government regarding cannabis, cannabis businesses in the U.S. are subject to inconsistent legislation and regulation. The Company is expected to remain focused in those U.S. states that have legalized the medical and/or adult-use of cannabis. Almost half of the U.S. states have enacted legislation to legalize and regulate the sale and use of medical cannabis without limits on THC, while other states have legalized and regulate the sale and use of medical cannabis with strict limits on the levels of THC. However, the U.S. federal government has not enacted similar legislation and the cultivation, sale and use of cannabis remains illegal under federal law pursuant to the CSA. The federal government of the U.S. has specifically reserved the right to enforce federal law in regard to the sale and disbursement of medical or adult-use use marijuana even if state law sanctioned such sale and disbursement. It is presently unclear whether the U.S. federal government intends to enforce federal laws relating to cannabis where the conduct at issue is legal under applicable state law. This risk was further heightened by the revocation of the Cole Memorandum in January 2018.

Further, there can be no assurance that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. It is also important to note that local and city ordinances may strictly limit and/or restrict the distribution of cannabis in a manner that will make it extremely difficult or impossible to transact business in the cannabis industry. If the U.S. federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing state laws are repealed or curtailed, then the Company's business would be materially and adversely affected. U.S. federal actions against any individual or entity engaged in the marijuana industry or a substantial repeal of marijuana related legislation could adversely affect the Company.

Nature of the Company's Involvement in the U.S. Cannabis Industry

Currently, the Company is engaged in the branding and procurement for companies that manufacture and distribute cannabis in the medical and adult-use cannabis marketplace. As at September 30, 2021, the Company's assets and revenues are primarily attributable to the medical marijuana use in the State of Arizona.

As previously stated, violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions, or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company, including its reputation and ability to conduct business, the listing of its securities on any stock exchange, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. The approach to the enforcement of cannabis laws may be subject to change or may not proceed as previously outlined.

The Company's involvement in the U.S. cannabis industry will be (i) only in those states that have enacted laws legalizing cannabis; and (ii) only in those states where the Company can comply with state (and local) laws and regulations and has the licenses, permits or authorizations to properly carry on each element of its business.

The Company will continue to monitor, evaluate and re-assess the regulatory framework in each state in which it may hold license, and the federal laws applicable thereto, on an ongoing basis; and will update its continuous

disclosure regarding government policy changes or new or amended guidance, laws or regulations regarding cannabis in the U.S.

Heightened Scrutiny

For the reasons set forth above, the Company's activities in the U.S. may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company's activities in the U.S. or any other jurisdiction, in addition to those described herein.

Change in Laws, Regulations and Guidelines

The Company's business operations will directly and indirectly be affected by a variety of laws, regulations and guidelines relating to the manufacture, management, transportation, storage and disposal of cannabis, but also including laws and regulations relating to consumable products health and safety, the conduct of operations and the protection of the environment. These laws and regulations are broad in scope and subject to evolving interpretations, which could require participants to incur substantial costs associated with compliance or alter certain aspects of its business plans. In addition, violations of these laws, or allegations of such violations, could disrupt certain aspects of the Company's business plans and result in a material adverse effect on certain aspects of its operations.

Unfavorable Publicity or Consumer Perception

The legal cannabis industry in the U.S. is at an early stage of its development. Cannabis has been, and will continue to be, a controlled substance for the foreseeable future. Consumer perceptions regarding legality, morality, consumption, safety, efficacy, and quality of cannabis are mixed and evolving. Consumer perception can be significantly influenced by scientific research or findings, regulatory investigations, litigation, media attention and other publicity regarding the consumption of cannabis products. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the cannabis market or any product, or consistent with earlier publicity. Future research reports, findings, regulatory opinion, and support for medical and adult-use cannabis use has traditionally been inconsistent and varies from jurisdiction to jurisdiction. While public opinion and support appears to be rising for legalizing medical and adult-use cannabis, it remains a controversial issue subject to differing opinions surrounding the level of legalization (for example, medical marijuana as opposed to legalization in general). The Company's ability to gain and increase market acceptance of its business activities may require substantial expenditures on proceedings, litigation, media attention or other publicity that are perceived as less favorable than, or that question, earlier research reports, findings or publicity could have a material adverse effect on the demand for cannabis and on the business, results of operations, financial condition, and cash flows of the Company. Further, adverse publicity reports or other media attention regarding cannabis in general or associating the consumption of cannabis with illness or other negative effects or events, could have such a material adverse effect. Public investor relations, strategic relationships, and marketing initiatives. There can be no assurance that such initiatives will be successful, and their failure may have an adverse effect on the Company.

Local, state, and federal laws and regulations governing marijuana for medicinal and recreational purposes are broad in scope and are subject to evolving interpretations, which could require the Company to incur substantial costs associated with bringing the Company's operations into compliance. In addition, violations of these laws, or allegations of such violations, could disrupt the Company's operations and result in a material adverse effect on its financial performance. It is beyond the Company's scope to predict the nature of any future change to the existing laws, regulations, policies, interpretations, or applications, nor can the Company determine what effect such changes, when and if promulgated, could have on the Company's business.

Other Regulatory Risks

The activities and products of the Company are subject to regulation by governmental authorities, including, the U.S. Food and Drug Administration, and others. Achievement of the Company's business objectives are contingent, in part, upon compliance with regulatory requirements enacted by these governmental authorities and obtaining all regulatory approvals, where necessary, for the sale of its products. The Company cannot predict the time required to secure all appropriate regulatory approvals for its products, or the extent of testing and documentation that may be required by governmental authorities. Any delays in obtaining, or failure to obtain regulatory approvals would significantly delay the development of markets and products and could have a material adverse effect on the business, results of operations and financial condition of the Company.

Reliance on Management

The success of the Company is dependent upon the ability, expertise, judgment, discretion, and good faith of its senior management. While employment agreements are customarily used as a primary method of retaining the services of key employees, these agreements cannot assure the continued services of such employees. Any loss of the services of such individuals could have a material adverse effect on the Company's business, operating results, or financial condition.

Additional Financing

In order to execute the anticipated growth strategy, the Company may require some additional equity and/or debt financing to support ongoing operations, to undertake capital expenditures or to undertake acquisitions or other business combination transactions. There can be no assurance that additional financing will be available when needed or on terms which are acceptable. The Company's inability to raise financing to support on-going operations or to fund capital expenditures or acquisitions could limit its growth and may have a material adverse effect upon future profitability.

If additional funds are raised through further issuances of equity or convertible debt securities, existing shareholders could suffer significant dilution, and any new equity securities issued could have rights, preferences, and privileges superior to those of holders of subordinated voting shares. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for the Company to obtain additional capital and to pursue business opportunities, including potential acquisitions.

Cannabis Industries are Highly Competitive

There is potential that the Company will face intense competition from other companies, some of which can be expected to have longer operating histories and more financial resources and manufacturing and marketing experience than the Company. Increased competition by larger and better financed competitors could materially and adversely affect the business.

Operating Risk and Insurance Coverage

The Company carries insurance to protect its assets, operations and employees. While the Company believes insurance coverage can adequately address all material risks to which it may be exposed and is adequate and customary in its current state of operations, such insurance is subject to coverage limits and exclusions and may not be available for the risks and hazards to which the Company is exposed. In addition, no assurance can be given that such insurance will be adequate to cover the Company's liabilities or will be generally available in the future or, if available, that premiums will be commercially justifiable. If the Company were to incur substantial liability and such damages were not covered by insurance or were more than policy limits, or if the Company were to incur such liability at a time when it is not able to obtain liability insurance, its business, results of operations and financial condition could be materially adversely affected.

Key Personnel Risk

The Company's success will depend on its directors and officers to develop the business and manage operations, and on its ability to attract and retain key quality assurance, scientific, sales, public relations and marketing staff or consultants. The loss of any key person or the inability to find and retain new key persons could have a material adverse effect on the business. Competition for qualified technical, sales and marketing staff, as well as for officers and directors, can be intense and no assurance can be provided that the Company will be able to attract or retain key personnel in the future, which may adversely impact operations.

Global Economy Risk

The ongoing economic slowdown and downturn of global capital markets has generally made the raising of capital by equity or debt financing more difficult. The Company will be dependent upon the capital markets to raise additional financing in the future, while it establishes a client base for its product. Access to financing has been negatively impacted by the ongoing global economic downturn. As such, the Company is subject to liquidity risks in meeting its development and future operating cost requirements in instances where cash positions are unable to be maintained or appropriate financing is unavailable. These factors may impact the Company's ability to raise equity or obtain loans and other credit facilities in the future and on terms favorable to the Company and its management. If uncertain market conditions persist, the Company's ability to raise capital could be jeopardized, which could have an adverse impact on its operations and, if applicable, the trading price of its subordinated voting shares on any stock exchange.

Dividend Risk

The Company has not paid dividends in the past and does not anticipate paying dividends in the near future. The Company expects to retain its earnings to finance further growth and, when appropriate, retire debt.

Securities and Dilution

There is no assurance that sources of financing will be available on acceptable terms, if at all. If the Company seeks additional equity financing, the issuance of additional shares will dilute the interests of their current shareholders. Failure to obtain such additional financings could result in delay or indefinite postponement of the Company's strategic goals.

Future Capital Requirements

The Company's future capital requirements will depend on many factors, including inorganic growth initiatives, securing new contracts, the rate of expansion and the status of competitive products. Depending on these factors, the Company may require additional financing which may or may not be available on acceptable terms. If additional funds are raised by issuing equity securities, dilution to the existing shareholders may result. If adequate funds are not available, the Company may not be able to achieve its growth objectives and operational targets, which could have a material adverse effect on the Company's business.

Novel Corona Virus Known as "COVID-19"

The Company may be impacted by business interruptions resulting from pandemics and public health emergencies, including those related to COVID-19. An outbreak of infectious disease, a pandemic, or a similar public health threat, such as the recent outbreak of COVID-19, or a fear of any of the foregoing, could adversely impact the Company by causing operating, manufacturing, supply chain, and project development delays and disruptions, labor shortages, travel, and shipping disruption and shutdowns (including as a result of government regulation and prevention measures). It is unknown whether and how the Company may be affected if such a pandemic persists for an extended period of time, including as a result of the waiver of regulatory requirements or the implementation of emergency regulations to which the Company is subject. Although the Company has been deemed essential and/or has been permitted to continue operating its facilities in the states in which it operates during the pendency of the

COVID-19 pandemic, there is no assurance that the Company's operations will continue to be deemed essential and/or will continue to be permitted to operate. The Company may incur expenses or delays relating to such events outside of its control, which the Company cannot estimate the length and severity of these developments or quantify the impact this pandemic may have on the financial results and condition of the Company in future periods.

OTHER INFORMATION

Additional information on the Company is available on SEDAR at www.sedar.com.